Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas
Pharma
Apellis' Syfovre faces tough road ahead in GA market: analyst
Despite holding the lead with its complement inhibitor Syfovre, Apellis is discovering that the geographic atrophy market is a tough nut to crack.
Fraiser Kansteiner
May 14, 2025 11:10am
Pharmas' Xi meeting; Tariffs; BioNTech—Fierce Pharma Asia
Apr 4, 2025 8:30am
Apellis expects sales of Syfovre to decline in Q1
Feb 28, 2025 3:05pm
Astellas, Mitsubishi Tanabe, Leqembi—Fierce Pharma Asia
Feb 14, 2025 9:51am
Astellas shifts investment focus to later-stage programs: exec
Feb 12, 2025 1:30pm
Merck, AstraZeneca, Astellas—Fierce Pharma Asia
Feb 7, 2025 9:00am
